| Name | Title | Contact Details |
|---|
In 1993, a novel technology was invented by a team that included Jon Faiz Kayyem, PhD at The California Institute of Technology (CalTech). This invention combined nucleic acids and microelectronics to produce an electronic sensor for DNA detection. His invention was based on electrical detection of nucleic acids on a cassette based detection platform. Dr. Kayyem went on to found Clinical Micro Sensors, with the goal of translating this “eSensor” technology to disposable chips. Following several acquisitions of the technology, Dr. Kayyem became actively involved again in 2009, returning as an investor and then as CEO and Chairman of the Board. In 2009, a collaboration between Dr. Kayyem and Christopher Gleeson began. The two redefined the company strategy, and brought in a new board of directors, executive leadership team, and commercial management. In 2010, the company known at that time as Osmetech, was named GenMark Diagnostics and listed on NASDAQ. Mr. Gleeson remained an integral part of GenMark`s growth in the years that followed, serving as Chairman of the Board until his retirement in 2014. Dr. Kayyem currently serves as SVP, Research and Development.
Integra LifeSciences Holdings Corporation, a world leader in regenerative medicine, is a global medical device company dedicated to improving the quality of life for millions of patients every year.
Hospicelink has created a nationally recognized , award winning software solution, specifically focused on the unique relationship between Hospice Companies and DME Providers. Although the needs of each Company can be vastly different, we understand the pressures in today`s marketplace and the difficulties these create for the industry. Hospicelink has addressed the challenges of providing optimal care while maintaining compliance and improving operational efficiencies, enabling your staff to balance multiple responsibilities. Hospicelink has a proven track record of helping clients solve these problems through our comprehensive set of innovative solutions. Our state-of-the-art application assists Hospice Companies and DME Providers with the ordering, billing, reporting and contract management processes. Hospicelink`s Executive Dashboard provides access to real-time actionable data, allowing a proactive response and improvement of identified inefficiencies.
We are the Southwest`s leading provider of comprehensive home healthcare products and services. We are committed to full-service homecare solutions that give our patients mobility and independence. Preferred Homecare/Lifecare Solutions has nearly 2,000 employees in over 60 locations, 7 Pharmacies, and 5 Ambulatory Infusion Suites, across the Western United States, all committed to offer the best care possible. We offer a full range of respiratory, home infusion and home medical equipment therapies and services. We are accredited by the Accreditation Commission for Health Care (ACHC). Meeting or exceeding each and every one of ACHC`s standards demonstrates our commitment to delivering the highest quality products and services to our patients. Our patient services teams include more than 750 highly skilled clinicians, (pharmacists, nurses, respiratory therapists, dietitians, and pharmacy techs) patient service technicians and customer service representatives all focused on providing unparalleled support, education, and prompt and courteous service. Your satisfaction with your care is our top priority. Our comprehensive line of products and services include: • Infusion Therapy • Specialty Pharmacy • Nutritional Products and Services, including enteral and parenteral • Respiratory Therapy • Oxygen Therapy • Sleep Apnea Products • Home Medical Equipment • Medical Supplies
OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.